In a subgroup analysis focused on patients with IBD, no increased risk of new or recurrent cancer was observed following exposure to TNF-α antagonists, with an incidence rate ratio (IRR) of 0.68 (95% CI: 0.40–1.16) [15]. This evidence concerns the gene TNF and inflammatory bowel disease.